Co-Authors
This is a "connection" page, showing publications co-authored by Jennifer Ku and Hung Tseng.
Connection Strength
8.046
-
Real-world Effectiveness of Adjuvanted RSVPreF3 Vaccine in Preventing RSV-associated Lower Respiratory Tract Disease Hospitalization in Adults =60 Years of Age: Early Results From a Test-negative Design Analysis. Open Forum Infect Dis. 2026 May; 13(5):ofag279.
Score: 0.978
-
Comparative Effectiveness of Licensed Influenza Vaccines in Preventing Influenza-related Medical Encounters and Hospitalizations in the 2022-2023 Influenza Season Among Adults =65 Years of Age. Clin Infect Dis. 2024 Nov 22; 79(5):1283-1292.
Score: 0.885
-
Effectiveness of a fourth dose of mRNA-1273 against COVID-19 among older adults in the United States: Interim results from an observational cohort study. Vaccine. 2023 06 29; 41(29):4212-4219.
Score: 0.799
-
Vaccine effectiveness of the mRNA-1273 3-dose primary series against COVID-19 in an immunocompromised population: A prospective observational cohort study. Vaccine. 2023 06 01; 41(24):3636-3646.
Score: 0.794
-
Risk of severe COVID-19 disease in individuals with Down syndrome: a matched cohort study from a large, integrated health care system. J Infect Dis. 2022 Jun 24.
Score: 0.749
-
Comparison of Healthcare Resource Utilization and Disease Outcomes in Adults Hospitalized with Human Metapneumovirus and Respiratory Syncytial Virus. J Infect Dis. 2026 Mar 17; 233(3):e651-e661.
Score: 0.242
-
Effectiveness and safety of the recombinant zoster vaccine in adults aged =50?years with inflammatory bowel disease. Hum Vaccin Immunother. 2025 Dec; 21(1):2576981.
Score: 0.238
-
Adjuvanted recombinant zoster vaccine is effective against herpes zoster ophthalmicus, and is associated with lower risk of acute myocardial infarction and stroke in adults aged =50 years. Clin Infect Dis. 2025 Aug 09.
Score: 0.232
-
Effectiveness of the Adjuvanted Recombinant Zoster Vaccine in Adults =50 Years in the United States. Clin Infect Dis. 2025 Jun 23.
Score: 0.230
-
Screening and vaccination rates for tetanus, hepatitis A, and hepatitis B among individuals with substance use disorders who are hospitalized in an integrated U.S. health system. Clin Infect Dis. 2025 May 20.
Score: 0.229
-
Effectiveness and safety of the recombinant zoster vaccine in individuals =50 years of age with rheumatoid arthritis: a matched cohort and self-controlled case series study. Ann Rheum Dis. 2025 Feb 19.
Score: 0.225
-
Comparative Effectiveness of Cell-Based Versus Egg-Based Influenza Vaccines in Prevention of Influenza Hospitalization During the 2022-2023 Season Among Adults 18-64?Years. Influenza Other Respir Viruses. 2024 Dec; 18(12):e70025.
Score: 0.222
-
Natural Language Processing Versus Diagnosis Code-Based Methods for Postherpetic Neuralgia Identification: Algorithm Development and Validation. JMIR Med Inform. 2024 Sep 10; 12:e57949.
Score: 0.218
-
Effectiveness and durability of mRNA-1273 BA.4/BA.5 bivalent vaccine (mRNA-1273.222) against SARS-CoV-2 BA.4/BA.5 and XBB sublineages. Hum Vaccin Immunother. 2024 Dec 31; 20(1):2335052.
Score: 0.212
-
Real-world effectiveness of recombinant zoster vaccine in self-identified Chinese individuals aged =50 years in the United States. Hum Vaccin Immunother. 2024 Dec 31; 20(1):2327145.
Score: 0.211
-
mRNA-1273 bivalent (original and Omicron) COVID-19 vaccine effectiveness against COVID-19 outcomes in the United States. Nat Commun. 2023 09 20; 14(1):5851.
Score: 0.204
-
Effectiveness of Messenger RNA-1273 Vaccine Booster Against Coronavirus Disease 2019 in Immunocompetent Adults. Clin Infect Dis. 2023 01 13; 76(2):252-262.
Score: 0.194
-
Effectiveness of mRNA-1273 vaccination against SARS-CoV-2 omicron subvariants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5. Nat Commun. 2023 Jan 12; 14(1):189.
Score: 0.194
-
Risk of herpes zoster following mRNA COVID-19 vaccine administration. Expert Rev Vaccines. 2023 Jan-Dec; 22(1):643-649.
Score: 0.194
-
Author Correction: Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants. Nat Med. 2022 May; 28(5):1095.
Score: 0.185
-
Durability of mRNA-1273 against COVID-19 in the time of Delta: Interim results from an observational cohort study. PLoS One. 2022; 17(4):e0267824.
Score: 0.185
-
Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants. Nat Med. 2022 Feb 21.
Score: 0.183
-
Effectiveness of mRNA-1273 against delta, mu, and other emerging variants of SARS-CoV-2: test negative case-control study. BMJ. 2021 12 15; 375:e068848.
Score: 0.180
-
Comparison of Hospitalization Costs Associated With Human Metapneumovirus and Respiratory Syncytial Virus Infection in US Adults. Open Forum Infect Dis. 2026 Apr; 13(4):ofag202.
Score: 0.061